perillyl alcohol

Phase 2Small molecule

UUniversity of Wisconsin, Madison

perillyl alcohol is one of 127 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

perillyl alcohol

UUniversity of Wisconsin, Madison

Phase 2

2 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00003219

Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy

Unknown status·TThe Cleveland Clinic·Phase 1·NCT00022425

Actinic Keratoses1 trial

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

Completed·UUniversity of Arizona·Phase 2·NCT00608634·89 enrolled

Refractory Cancer1 trial

Perillyl Alcohol in Treating Patients With Refractory Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00002862·25 enrolled

Glioma1 trial

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Recruiting·NNeonc Technologies, Inc.·Phase 1/2·NCT02704858·49 enrolled

Pancreatic Cancer1 trial

Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer

Completed·IIndiana University School of Medicine·Phase 2·NCT00003769

1 more indication

Metastatic Prostate Cancer1 trial

Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00003238

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for perillyl alcohol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — perillyl alcohol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for perillyl alcohol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Wisconsin, Madison

perillyl alcohol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Actinic Keratoses1 trial

Refractory Cancer1 trial

Glioma1 trial

Pancreatic Cancer1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News